Has David Shore, MD received payments from drug or device companies?

Yes. Drug and device makers reported $82,731 in general payments to David Shore, MD across 719 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Shore, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Shore, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Shore, MD

Endocrinology, Diabetes & Metabolism · Lawrenceville, GANPI 1619065067

Payments from drug & device makers

$82,731in general payments, 2019–2025

Across 719 payments — averaging $115.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Dexcom, Inc.$43K
Abbott$18K
Ascensia Diabetes Care US Inc.$4K
Corcept Therapeutics$3K
Novo Nordisk$3K
Amgen$2K
plus $10K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Dexcom, Inc.	53	$43,130
Abbott	87	$17,930
Ascensia Diabetes Care US Inc.	7	$3,511
Corcept Therapeutics	30	$3,069
Novo Nordisk	107	$2,864
Amgen(2 entities)	59	$2,127
Tandem Diabetes Care, Inc.	35	$1,270
Sanofi-aventis U.S. LLC	53	$1,249
Insulet Corporation	22	$749
AstraZeneca(2 entities)	34	$688
Medtronic(2 entities)	12	$659
IBSA Pharma Inc.	4	$543
Lilly USA, LLC	24	$542
Xeris Pharmaceuticals, Inc.	20	$402
BETA Bionics, Inc.	7	$321
Bayer	9	$228
Radius Health, Inc.	12	$228
Sequel Med Tech, LLC	3	$212
Bigfoot Biomedical Inc	4	$212
AbbVie	15	$207
Amarin Pharma, Inc.	12	$201
Johnson & Johnson	6	$174
Amneal Pharmaceuticals LLC	11	$171
Madrigal Pharmaceuticals	2	$161
GRT US Holding, Inc.	2	$142
Mannkind Corporation	8	$139
Galvanize Therapeutics, Inc	1	$137
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	8	$136
Boehringer Ingelheim	7	$125
Cequr Corporation	4	$114
Ascendis Pharma Endocrinology Inc	2	$109
Esperion Therapeutics, Inc.	5	$92
Vivus LLC	7	$92
BD	3	$60
Amphastar Pharmaceuticals, Inc.	3	$56
Regeneron Healthcare Solutions, Inc.	4	$54
Verity Pharmaceuticals Inc.	3	$51
Ultragenyx Pharmaceutical Inc.	2	$50
Nevro Corp.	2	$48
Kyowa Kirin, Inc.	2	$45
Lifescan, Inc.	2	$35
Currax Pharmaceuticals LLC	2	$30
Merck	2	$28
Companion Medical, Inc.	2	$26
Ipsen Biopharmaceuticals, Inc	1	$24
Senseonics, Incorporated	1	$23
Pfizer	1	$20
Embecta Corp.	1	$19
Astellas Pharma US Inc	1	$18
Neurocrine Biosciences, Inc.	1	$18
Novartis	1	$18
Theracosbio, LLC	2	$17
Eisai Inc.	1	$17
Organon	1	$16
Nalpropion Pharmaceuticals LLC	1	$15
Averitas Pharma Inc.	1	$15
Roche Diabetes Care, Inc.	1	$14
Silk Road Medical, Inc.	1	$14
Ionis Pharmaceuticals, Inc.	1	$14
Antares Pharma, Inc.	1	$14

How this compares

$82,731 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024

$202,829

Medicare patients

596

Services billed

2,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Lawrenceville

Adeniyi OdugbesanLawrenceville$1.8M
David ArkinLawrenceville$15K
Aparna MahakalaLawrenceville$12K
Bruce BodeAtlanta$18.3M
Gulliermo UmpierrezAtlanta$6.6M
John ReedRoswell$5.7M
Thomas JonesMacon$4.8M
Steven LeichterColumbus$3.1M
Jason BernerJasper$2.6M
Ashwini GoreMacon$2.6M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →